CONVOCATION OF AN EXTRAORDINARY SHAREHOLDERS' MEETING OF POLYPHOR LTD ON THURSDAY, OCTOBER 28, 2021

Dear Shareholder,

We hereby invite you to an Extraordinary Shareholders’ Meeting of Polyphor Ltd (the "Company").

Due to the current restrictions resulting from the Covid-19 pandemic, the meeting will be held without physical attendance of shareholders. Only voting in written form is permitted. We therefore foresee to have an information call in advance as follows:

**Information Call:** October 14, 2021, 14:00 CET

please use the following dial in:

- **CH:** +41 44 580 7206
- **DE:** +49 69 2222 25574
- **FR:** +33 1 70 72 25 50
- **IT:** +39 02 3600 8019
- **UK:** +44 330 336 9125
- **US:** +1 646-828-8193

Confirmation Code: 6712283

The link for the webcast without audio (for those who called through the dial-in):
https://www.webcast-eqs.com/polyphor20211014/no-audio

The link for the webcast for those who don’t want to dial-in:
https://www.webcast-eqs.com/polyphor20211014

**Return of reply forms:**

We ask all shareholders to return the signed reply form with the enclosed (pre-paid) envelope to Nimbus AG (address indicated on the top of the reply form) or to register for online voting as indicated in the reply form prior to October 25, 2021. Online voting will close on October 26, 2021 at 23:59 CET. As agenda items 1, 2, 3 and 4 require a majority of two thirds of all shares represented at the meeting in order to pass, we invite you to vote either "yes" or "no" on these items (abstentions would effectively be "no" votes).

The meeting will be held at the offices of the Company at Hegenheimermattweg 125, 4123 Allschwil at 14:00 CET without the physical attendance of shareholders.

With this convocation, you receive the following documents:

1. This convocation with the agenda
2. Reply form

Supporting information can be found in the shareholder letter which was sent with this convocation and which has also been published on the Company's website.

With best regards,

Kuno Sommer  Gökhan Batur
Chairman  Chief Executive Officer
AGENDA OF THE MEETING

1. Ordinary Capital Increase*

In order to implement a merger with EnBiotix Inc. ("Enbiotix"), a privately held late clinical-stage rare disease company currently focused on products for rare, chronic respiratory diseases, the Board of Directors ("Board") proposes to increase the Company's ordinary share capital as follows:

a) The ordinary share capital of the Company shall be increased by up to CHF 789'259.34 by issuance of up to 39'462'967 registered shares with a nominal value of CHF 0.02 each;

b) The subscription price of the new registered shares shall be determined by the Board;

c) The pre-emptive rights of the shareholders for the newly issued registered shares shall be excluded and allocated to the holders of Enbiotix's capital stock. Unexercised subscription rights shall lapse.

d) The new registered shares shall be entitled to dividends for the business year starting 1 January 2021;

e) The new shares shall be subject to the transfer restrictions as outlined in article 4 of the articles of association;

f) The stamp duty shall be paid by the Company;

g) The Board of Directors is authorized and instructed to implement and register this capital increase with the competent commercial register within the legal deadline. Any notary of VISCHER AG shall be individually authorized to amend the documents to be filed with the competent commercial register where necessary or take the corresponding resolutions in a continuation of the current shareholders' meeting.

Background: Under the proposed merger, Polyphor shall acquire all of the outstanding capital stock of EnBiotix in exchange for registered shares of Polyphor. The transaction is subject to a number of closing conditions, including approval by Polyphor and EnBiotix shareholders, satisfactory completion of due diligence and satisfactory assessment of tax consequences. Upon completion of the merger, former EnBiotix equity holders (including investors of the planned financing round) are expected to own approximately 74-77% of Polyphor's common stock. Polyphor's current shareholders are expected to own approximately 23-26% of Polyphor's issued common shares following the closing of the merger. Following closing, expected in Q4 2021, Polyphor will be renamed and is expected to trade under a new ticker symbol on the Swiss Stock Exchange. The transaction has been unanimously approved by the board of directors of both companies.

2. Renewal and Increase of the Authorized Share Capital

The Board of Directors proposes to renew and increase the authorized share capital to comprise 20'530'008 registered shares with a nominal value of CHF 0.02 each and to amend article 3a paragraph 1 of the articles of association to read as follows:

* Numbers do not reflect registered shares issued from the Company's conditional share capital in connection with the exercise of stock options and convertible bonds in 2021 but not yet registered in the commercial register. If these shares have also been registered at the date of the shareholder meeting, the numbers in this resolution will be adjusted accordingly.
Art. 3a Authorized Share Capital

The Board of Directors is authorized to increase the share capital, at any time until October 27, 2023, by a maximum amount of CHF 410'600.16 by issuing a maximum of 20'530'008 registered shares with a par value of CHF 0.02 each, to be fully paid up. An increase of the share capital (i) by means of an underwriting (ii) by a subsidiary in view of and related to any of the below mentioned transactions allowing an exclusion of the preemptive rights and (iii) in partial amounts shall be permissible.

This resolution is conditional upon the resolution of the Board confirming the capital increase in conjunction with the proposed merger in agenda item 1.

The Board shall be authorized to reduce the numbers in this resolution to the extent required to stay below the legal maximum authorized share capital allowed in law (50% of the ordinary share capital).

Background: At the Company's annual general meeting in 2020, the shareholders approved the creation of an authorized share capital in the amount of 50% of the Company's then current ordinary share capital. This authorized share capital was never used. This request to increase the authorized share capital would allow the Company to maintain roughly 50% of the ordinary share capital to be available based on the new capital structure of the Company following the merger. With this request, the Company intends to gain strategic flexibility that aligns with the outlined strategy and should allow financing of the following phases of development, at the appropriate time as the pipeline and Company value develops.

3. Increase of Conditional Share Capital for Bonds and Similar Debt Instruments

The Board of Directors proposes to increase the conditional share capital for bonds and similar debt instruments by 8'138'843 to comprise 10'199'256 registered shares with a nominal value of CHF 0.02 each and to amend article 3b paragraph 1 of the articles of association to read as follows:

Art. 3b Conditional Capital for Bonds and Similar Debt Instruments

The share capital of the Company shall be increased by a maximum amount of CHF 203'985.12 through the issuance of a maximum of 10'199'256 registered shares, payable in full, each with a nominal value of CHF 0.02 through the exercise of conversion and/or option rights granted in connection with

Art. 3b Bedingtes Kapital für Anleiheobligationen oder ähnliche Instrumente

Das Aktienkapital der Gesellschaft wird im Maximalbetrag von CHF 203'985.12 durch Ausgabe von höchstens 10'199'256 vollständig zu liberierenden Namenaktien mit einem Nennwert von CHF 0.02 je Aktie erhöht durch die Ausübung von Wandlungs-

* Numbers do not reflect registered shares issued from the Company’s conditional share capital in connection with the exercise of convertible bonds in 2021 but not yet registered in the commercial register. If these shares have also been registered at the date of the shareholder meeting, the numbers in this resolution will be adjusted accordingly.
This resolution is conditional upon the resolution of the Board confirming the capital increase in conjunction with the proposed merger in agenda item 1.

Background: The Board proposes to adjust the conditional capital for bonds and similar debt instruments as set out above in order to facilitate potential financing activities of the merged entity. Conditional capital has certain advantages over authorized capital and is aimed at ensuring flexibility in the capital structure of the Company, typically for smaller and short-term financing needs. The issuance of equity under financing facilities that are foreseen under this authorization typically have the advantage to be used on an “only if needed” basis and serve as a short-term bridge which minimizes unnecessary dilution to existing shareholders.

4. Creation of new Conditional Share Capital for Employee Benefit Plans

The Board of Directors proposes to create a new conditional share capital for employee benefit plans and to adopt the following new article 3d of the articles of association:

<table>
<thead>
<tr>
<th>Art. 3d</th>
<th>Conditional Share Capital for Employee Benefit Plans</th>
</tr>
</thead>
<tbody>
<tr>
<td>Art. 3d</td>
<td>Bedingtes Aktienkapital für Mitarbeiterbeteiligungspläne</td>
</tr>
</tbody>
</table>

The Board of Directors proposes to create a new conditional share capital for employee benefit plans and to adopt the following new article 3d of the articles of association:

<table>
<thead>
<tr>
<th>Art. 3d</th>
<th>Conditional Share Capital for Employee Benefit Plans</th>
</tr>
</thead>
<tbody>
<tr>
<td>Art. 3d</td>
<td>Bedingtes Aktienkapital für Mitarbeiterbeteiligungspläne</td>
</tr>
</tbody>
</table>

The purchase of registered shares in connection with employee participation and any further transfers

Shareholders’ subscription rights shall be excluded with regard to these shares. These new registered shares may be issued at a price below the current market price. The Board of Directors shall specify the precise conditions of issue including the issue price of the shares.

Shareholders’ subscription rights shall be excluded with regard to these shares. These new registered shares may be issued at a price below the current market price. The Board of Directors shall specify the precise conditions of issue including the issue price of the shares.

Der Erwerb von Namenaktien im Zusammenhang der Mitarbeiterbeteiligung sowie sämtliche weiteren Übertragungen von Namenaktien unterliegen den
This resolution is conditional upon the resolution of the Board confirming the capital increase in conjunction with the proposed merger in agenda item 1.

**Background:** The Board proposes to create a separate conditional capital for any future option issuances for employee benefit plans of the merged entity. This serves to better separate new option issuances from legacy options issued under article 3c of the articles of association. The conditional share capital for employee benefit plans allows the Company to offer options to its employees, based on performance and retention schemes. This will allow the merged company to be an attractive employer both to attract and retain talent.

5. **Discharge of the Board of Directors and Executive Management**

The Board of Directors proposes that the members of the Board of Directors and Executive Management be granted discharge for the year 2021 up to the date of this shareholder meeting.

This resolution is conditional upon the resolution of the Board confirming the capital increase in conjunction with the proposed merger in agenda item 1.

6. **Election to the Board of Directors**

Subject to the closing of the merger, Andreas Wallnöfer, Silvio Inderbitzin and Hugh O'Dowd have announced their intention to resign from the Board as of such closing. In their stead, the Board of Directors proposes to elect Jeffrey D. Wager as chairman and new member of the Board, and to elect Dennis Ausiello, Dan Hartman and Robert Clarke as new members of the Board, each for the term until the next Annual Shareholders’ Meeting:

6.a **Election of Jeffrey D. Wager as chairman and member of the Board**  
6.b **Election of Dennis Ausiello as member of the Board**  
6.c **Election of Dan Hartman as member of the Board**  
6.d **Election of Robert Clarke as member of the Board**

This resolution is conditional upon the resolution of the Board confirming the capital increase in conjunction with the proposed merger in agenda item 1.
Jeffrey D. Wager, M.D.
Between 2011-2017, Jeff Wagner was co-creator and board observer to Grupo Biotoscana SL, a Latin American specialty pharma roll-up financed by Advent International and Essex Woodlands Healthcare Ventures, focused on cancer, infectious and rare diseases, leading to its USD 1 billion 2017 IPO on sales of ~$240M and 600 staff in 10 LatAm markets. From 2006 – 2010, he formed and led Artisan Pharma, Inc. as its founding CEO, raising $53M, building the entire team and implementing a 750 patient, 17 country Phase IIb/III study ultimately leading to Artisan’s acquisition by Asahi Kasei Pharma Corporation (Japan) in 2011. In 2000, Jeff formed Apeiron Partners, a FINRA-registered life sciences investment bank focused on corporate spin-outs, M&A, corporate venture capital and principal investments. In the process, successfully completed six spin-outs, including Targacept, Inc. (NASDAQ: TRGT), Artisan Pharma (from Asahi Kasei), Biocritica ($120M annual revenue Xigris® franchise from Eli Lilly) and KBI BioPharma (acquired by JSR Corporation (Japan)). Between 2003 and 2006, advised on the establishment and investment of Z-Cube s.r.l., the €60M corporate venture fund of the Zambon Group, a privately held Italian pharmaceutical company. Between 1995-2000, Jeff was with Medical Science Partners, a Harvard-founded VC fund focused on forming spin-outs from the Harvard medical system, including deCODE, ICAgen, Inspire, Oravax (subsequently Acambis), ZYCOS, Inc. and Diatide, amongst others. Jeff Wagner began his career with a life sciences unit of the Bank of Tokyo, where he led business development, responsible for helping Japanese pharmaceutical clients establish overseas affiliates, design, and conduct overseas clinical development and strategy alliances. Jeff is also a co-founder and Chairman of Proterris, Inc., a phase II/III clinical-stage firm focused on therapeutic uses of low-dose gaseous and small molecule carbon monoxide for transplant, fibrosis, and oncology indications. Jeff Wager earned his MD from Rush Medical College and his MBA from the University of Chicago.

Dennis Ausiello, M.D.
Dennis A. Ausiello is the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School. He is concurrently the Director, Emeritus of the Harvard Medical School’s M.D./Ph.D. Program. He is also Chair of Medicine, Emeritus, and Director of the Center for Assessment Technology and Continuous Health (CATCH) at Massachusetts General Hospital. Dennis was the former Lead Director of the board of directors at Pfizer, Inc. Previously, and served as an editor of Cecil’s Textbook of Medicine. Dennis Ausiello serves on the board of directors of Alnylam Pharmaceuticals and Seres Therapeutics, Inc. and previously served on the board of directors of Pfizer, where he currently serves on the advisory board. Dennis received his B.S. from Harvard College and his M.D. from the University of Pennsylvania School of Medicine. Throughout his career, Dennis Ausiello has made substantial contributions to the study of epithelial biology in the areas of membrane protein trafficking, ion channel regulation and signal transduction, and has published numerous articles, book chapters and textbooks.
**Dan Hartman, M.D.**

Dan Hartman is currently Director, Integrated Development for the Gates Foundation, leading a team that provides technical expertise in product development to other foundation teams and their partners. He joined the foundation in 2012 in his current role and served simultaneously as interim director of the Malaria team from 2016 to 2018. Dan has extensive management and pharmaceutical experience. Before joining the foundation, he served for four years as president and CEO of Great Lakes Drug Development, a consulting company providing strategic and operational support for early drug development projects. Previously, he served as senior vice president of product development at deCODE genetics, executive director of Pfizer Global Research and Development, and vice president of global clinical development at Esperion Therapeutics, and he held clinical research positions at Eli Lilly & Company. He has also provided consultation to the biopharmaceutical venture capital community and serves as a member/advisor on several nonprofit boards. Dan served as a member of the National Institutes of Health’s National Center for Advancing Translational Sciences and Cures Acceleration Network advisory board from 2016 to 2019 and was president of the American Society for Clinical Pharmacology & Therapeutics. Dan Hartman has received numerous awards, including Inventor of the Year from the Intellectual Property Owners Association. He received his bachelor’s degree from Calvin College and his medical degree from Wayne State University. Dan was trained in internal medicine and completed a fellowship in pulmonary medicine at Indiana University, where he also served as chief medical resident.

**Robert Clarke, Ph.D.**

Robert Clarke, has served as Chief Executive Officer / Board Member / Co-founder of Kinaset Therapeutics since 2020. He was previously Chief Executive Officer at Pulmatrix Inc. (NASDAQ: PULM), a clinical-stage respiratory drug delivery company, from 2012 to 2019 and successfully brought the company public in 2015. He joined Pulmatrix in 2004 as the first Ph.D.-level scientist and was appointed Chief Scientific Officer in 2010. In that role he was focused on developing the Pulmatrix technologies for the treatment of respiratory diseases. During his tenure as Chief Executive Officer, Pulmatrix raised more than $50 million in public equity, $80 million in venture capital funding and more than $10 million in non-dilutive funding to support the company’s development programs. Prior to his tenure at Pulmatrix, Robert was Associate Director, Life Sciences at Alkermes. He holds Board seats at several institutions including Johns Hopkins University and Boston University College of Engineering. Robert Clarke holds a Ph.D. in physiology from Johns Hopkins University and completed his post-doctoral training in respiratory biology at Brigham and Women’s Hospital and Harvard University.

### 7. Election of the Members of the Compensation Committee

In light of the revised Board composition as of closing of the merger, the Board of Directors proposes to elect Kuno Sommer, Dan Hartman and Robert Clarke as the new members of the compensation committee, each for the term until the next Annual Shareholders’ Meeting.

7.a Election of Kuno Sommer
7.b Election of Dan Hartman
7.c Election of Robert Clarke
8. **Name Change**

The Board of Directors proposes to change the Company’s name to Spexis AG and to amend the heading and article 1 of the articles of association to read as follows:

<table>
<thead>
<tr>
<th>ARTICLES OF ASSOCIATION</th>
<th>STATUTEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>of Spexis AG (Spexis SA) (Spexis Ltd)</td>
<td>der Spexis AG (Spexis SA) (Spexis Ltd)</td>
</tr>
<tr>
<td>with registered office in Allschwil</td>
<td>mit Sitz in Allschwil</td>
</tr>
</tbody>
</table>

(Translation; in case of controversy the German text shall prevail)

| I. CORPORATE NAME, PRINCIPAL OFFICE, DURATION AND PURPOSE OF THE COMPANY |
| I. FIRMA, SITZ, DAUER UND ZWECK DER GESELLSCHAFT |
| Art. 1 Corporate Name, Principal Office and Duration |
| Art. 1 Firma, Sitz und Dauer |
| Under the name Spexis AG (Spexis SA) (Spexis Ltd) |
| Unter der Firma Spexis AG (Spexis SA) (Spexis Ltd) |

there exists a Company which is subject to the provisions of Art. 620 et seq. of the Swiss Code of Obligations (CO) with registered office in Allschwil. The duration of the Company is unlimited.

This resolution is conditional upon the resolution of the Board confirming the capital increase in conjunction with the proposed merger in agenda item 1.
9. **Vote on Additional Fixed (Non-Performance-Related) Compensation for Members of the Board of Directors until the next Annual Shareholders' Meeting**

The Board of Directors proposes that shareholders approve an additional CHF 13'000 of fixed (non-performance-related) compensation for the members of the Board of Directors for the period until the next Annual Shareholders' Meeting.

This resolution is conditional upon the resolution of the Board confirming the capital increase in conjunction with the proposed merger in agenda item 1.

*Background: In light of the increased number of Board members, the total compensation for members of the Board needs to be adjusted accordingly.*

10. **Vote on Additional Equity Based Compensation for Members of the Executive Management for 2022**

The Board of Directors proposes that shareholders approve the grant of a maximum of 435'000 additional options for the members of the Executive Management for the year 2022, with a current maximum value of such additional options of CHF 507'950 with quarterly vesting over four years plus the related social security costs (estimate based on current value: CHF 33'017).

This resolution is conditional upon the resolution of the Board confirming the capital increase in conjunction with the proposed merger in agenda item 1.

*Background: In order to be able to offer competitive salaries to attract and retain talent going forward and in light of the reduced share value, the Board proposes to increase the total number of options available for allocation to members of the Executive Management. If approved, the current maximum value of all options available for EC members for 2022 is still well below the CHF 1'100'000 approved at the previous annual general meeting.*
REPLY FORM

Extraordinary Shareholders' Meeting of Polyphor Ltd, October 28, 2021

Instruction

I authorize the independent proxy lic. iur. Marius Meier, Attorney at Law and Notary Public, Lautengartenstrasse 7, CH-4052 Basel, Switzerland, or another person authorized by him to represent me at the Extraordinary Shareholders' Meeting and to cast my votes in accordance with my instructions on the back of this form. In the absence of any specific instructions on the instruction form, I hereby authorize the independent proxy to cast my votes in support of the proposals by the Board of Directors.

Electronic proxy voting and instructions to the independent voting rights representative

You have the possibility to cast a proxy voting to the independent voting rights representative electronically (online). You can register yourself under https://polyphor.shapp.ch with your personal login details:

Login: Password:

With my / our signature, I / we also confirm to be the shareholder according to the details on the back of this form and to be able to validly sign this form.

Date: ______________________ Signature: ______________________

Date: ______________________ Signature*: ______________________

* The second signature is mandatory if required by legal persons for a valid authorization.

Please return this Reply Form with enclosed envelope prior to October 25, 2021 to the address indicated on the top of this reply form, thank you. The enclosed envelope is pre-paid, so it is not necessary to add a postal stamp.
INSTRUCTIONS FOR THE INDEPENDENT PROXY

**General Instruction**

This general instruction relates to all agenda items in the convocation. By checking Yes you support the proposal of the Board of Directors. If you wish to deviate from this for a specific agenda item, then please mark a different instruction in such agenda item below.

<table>
<thead>
<tr>
<th>Proposals (according to agenda):</th>
<th>Yes</th>
<th>No</th>
<th>Abstention*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Ordinary Capital Increase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Renewal and Increase of the Authorized Share Capital</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Increase of Conditional Share Capital for Bonds and Similar Debt Instruments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Creation of new Conditional Share Capital for Employee Benefit Plans</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Discharge of the Board of Directors and Executive Management</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Election to the Board of Directors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.a Election of Jeffrey D. Wager (chairman and member)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.b Election of Dennis Ausiello (member)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.c Election of Dan Hartman (member)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.d Election of Robert Clarke (member)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Election of the Members of the Compensation Committee</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.a Election of Kuno Sommer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.b Election of Dan Hartman</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.c Election of Robert Clarke</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Name Change to Spexis AG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Vote on Additional Fixed (Non-Performance-Related) Compensation for Members of the Board of Directors until the next Annual Shareholders’ Meeting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Vote on Additional Equity Based Compensation for Members of the Executive Management for 2022</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In the event of new agenda items or other proposals during the Extraordinary Shareholders’ Meeting the Independent Proxy shall vote as proposed by the Board.

* As agenda items 1, 2, 3 and 4 require a majority of two thirds of all shares represented at the meeting in order to pass, we invite you to vote either "yes" or "no" on these items (abstentions would effectively be "no" votes).